Matt Holian is a partner in DLA Piper's Product Liability and Mass Tort practice group, recognized in 2015 by Chambers as a finalist for Product Liability Practice Group of the Year, in 2014 by Legal 500 as a ''top-tier'' firm in the field, and by Law360 as the 2013 Product Liability Group of the Year. Matt's practice involves the defense of pharmaceutical and other healthcare companies in a variety of cases, with an emphasis on serving as national counsel in complex, multi-jurisdictional product liability suits. Matt serves as the Co-Chair of the firm's US Life Sciences Sector.

Matt provides strategic advice in managing mass torts from start to finish, beginning with litigation risk assessments before medications are approved and continuing through pretrial discovery, bellwether trials and, ultimately, resolution.

Matt has played a leadership role in a number of federal multi-district litigations and related state court proceedings for some of the world's largest pharmaceutical companies. He also has played a significant role in expert discovery in those litigations, particularly relating to epidemiology and statistics.

Matt also has litigated cases involving alleged consumer fraud and other class actions, trade secret misappropriation, patent and trademark infringement, and commercial disputes primarily relating to licensing agreements in the pharmaceutical and biotech industry.

In addition to his litigation practice, Matt also counsels clients regarding research and development issues (including claims by patients in clinical trials), compliance issues and risk mitigation practices.